SCHEMBL2284036

SCHEMBL2284036

Oc1nc2ccccc2cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
GLA P06280 3/20 0.53
HPGD P15428 3/20 0.52
MAPT P10636 2/20 0.52
ACHE P22303 1/20 0.52
GAA P10253 3/20 0.48
STAT3 P40763 1/20 0.48
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 2/20 0.41
NQO2 P16083 2/20 0.40
HTR3A P46098 1/20 0.39
IKBKB O14920 1/20 0.39
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
PTBP1 P26599 1/20 0.38
RAB9A P51151 1/20 0.38
RCE1 Q9Y256 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30685964 1.00 ALDH1A1 (0.53) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL29911341 0.77 KMT2A (0.59) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL244868 0.77 KMT2A (0.59) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL7159163 0.77 ALDH1A1 (0.63) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL38652592 0.77 ALDH1A1 (0.63) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL209889 0.77 ALDH1A1 (0.63) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL14915531 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EGLAHPGDMAPT
Water SCHEMBL14722626 0.76 ALDH1A1 (0.61) ALDH1A1KDM4EGLAHPGDMAPT
Hydrochloric Acid SCHEMBL5594900 0.76 ALDH1A1 (0.61) ALDH1A1KDM4EGLAHPGDMAPT
SCHEMBL31047153 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EGLAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119770669-A Preparation method and application of targeted co-delivery system based on pMMP-1 and hydroxychloroquinoline 中国人民解放军空军军医大学 2025-04-08 CN claimed
CN-117122576-A Preparation method and application of hydroxychloroquinoline targeted nano drug delivery system 中国人民解放军空军军医大学 2023-11-28 CN claimed
CN-110862345-B Preparation method of salazosulfapyridine intermediate 苏州黄河制药有限公司 2022-03-11 CN claimed
US-20210093724-A1 TOPICAL ANTI-ACNE COMPOSITION CONCEPT MATRIX SOLUTIONS 2021-04-01 US claimed
CN-111704633-A Mo catalyst and application thereof in preparation of 9, 10-epoxy-1, 5-cyclododecadiene 万华化学集团股份有限公司 2020-09-25 CN claimed
CN-110862345-A Preparation method of salazosulfapyridine intermediate 苏州黄河制药有限公司 2020-03-06 CN claimed
US-20140154342-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS SANTALIS PHARMACEUTICALS INC. (US) 2014-06-05 US claimed
EP-2736504-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS Santalis Pharmaceuticals Inc. (US) 2014-06-04 EP claimed
CN-103796650-A Sandalwood oil and its uses related to skin disorders SANTALIS PHARMACEUTICALS INC 2014-05-14 CN claimed
WO-2014031769-A2 TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2014-02-27 WO claimed
WO-2013016656-A1 SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS SANTALIS PHARMACEUTICALS INC. (US) 2013-01-31 WO claimed
WO-2009140215-A2 METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS GERAGHTY, ERIN (US) 2009-11-19 WO claimed
US-20080207673-A1 Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins XILINAS MICHEL 2008-08-28 US claimed
WO-2006117660-A2 METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS CLIO PHARMACEUTICAL CORPORATION (US) 2006-11-09 WO claimed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-4228163-A WITH BENZOYL PEROXIDE AND 5-CHLORO-8-HYDROXYQUINOLINE DERMIK LABORATORIES (US) 1980-10-14 US claimed
US-4166118-A USE OF CHLORHYDROXYQUINOLINE TO INHIBIT GROWTH OF MYCOPLASMAS E. R. SQUIBB & SONS, INC. (US) 1979-08-28 US claimed
CN-119770669-B Preparation method and application of targeted co-delivery system based on pMMP-1 and hydroxychloroquinoline 中国人民解放军空军军医大学 2025-10-17 CN disclosed
US-4164564-A MINERAL OIL, ESTERS OF ISOSTEARIC ACID E. R. SQUIBB & SONS, INC. (US) 1979-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093724-A1 TOPICAL ANTI-ACNE COMPOSITION CUTA, EBP, CNR2 ALDH1A1 2679/4885KDM4E 2768/4885GLA 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.